Literature DB >> 23687290

Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.

Valentina Cambiano1, Silvia Bertagnolio, Michael R Jordan, Jens D Lundgren, Andrew Phillips.   

Abstract

Scale-up of antiretroviral therapy in low- and middle-income countries has been achieved by using a public health approach that involved national standard regimens and clinical monitoring in settings where laboratory infrastructure was not available. This strategy potentially allows for long periods of unrecognized viral failure, during which drug-resistant virus can be transmitted and this could compromise the long-term effectiveness of currently available first-line regimens. In response to this concern, the World Health Organization recommends population-based surveys to detect whether the prevalence of resistance in ART-naive people is reaching alerting levels. Whereas adherence counseling has to be an integral component of any treatment program, it is still unclear which threshold of transmitted drug resistance (TDR) should trigger additional targeted public health actions and which action is the most cost-effective. Mathematical models can contribute to answer these questions. In order to estimate the potential long-term impact of TDR on mortality in people on ART we used the Synthesis transmission model. TDR is predicted to have potentially significant impact on future HIV mortality. It is critical to remain vigilant over transmission of drug-resistant HIV.

Entities:  

Keywords:  HIV; antiretroviral therapy; mathematical model; mortality; resource-limited settings; transmitted drug resistance

Mesh:

Substances:

Year:  2013        PMID: 23687290     DOI: 10.1093/infdis/jit111

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa.

Authors:  Benjamin Chimukangara; Ayesha B M Kharsany; Richard J Lessells; Kogieleum Naidoo; Soo-Yon Rhee; Justen Manasa; Tiago Gräf; Lara Lewis; Cherie Cawood; David Khanyile; Karidia Diallo; Kassahun A Ayalew; Robert W Shafer; Gillian Hunt; Deenan Pillay; Salim Karim Abdool; Tulio de Oliveira
Journal:  AIDS Res Hum Retroviruses       Date:  2019-01-07       Impact factor: 2.205

2.  Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10.

Authors:  Quang Duy Pham; Nhan Thi Do; Yen Ngoc Le; Thuong Vu Nguyen; Duc Bui Nguyen; Thu Khanh Hoang Huynh; Duong Duc Bui; Nghia Van Khuu; Phuc Duy Nguyen; Anh Que Luong; Hien Thu Bui; Hai Huu Nguyen; Michelle McConnell; Long Thanh Nguyen; Lei Zhang; Lien Xuan Truong
Journal:  J Antimicrob Chemother       Date:  2014-11-27       Impact factor: 5.790

3.  Patients' and Providers' Views on Optimal Evidence-Based and Scalable Interventions for Individuals at High Risk of HIV Treatment Failure: Sequential Explorations Among Key Stakeholders in Cape Town, South Africa.

Authors:  Lora L Sabin; Allen L Gifford; Jessica E Haberer; Kelsee Harvey; Natalya Sarkisova; Kyle Martin; Rebecca L West; Jessie Stephens; Clare Killian; Nafisa Halim; Natacha Berkowitz; Karen Jennings; Lauren Jennings; Catherine Orrell
Journal:  AIDS Behav       Date:  2022-02-21

Review 4.  Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.

Authors:  Richard J Lessells; Ava Avalos; Tulio de Oliveira
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

5.  Tuberculosis in Cape Town: An age-structured transmission model.

Authors:  Nello Blaser; Cindy Zahnd; Sabine Hermans; Luisa Salazar-Vizcaya; Janne Estill; Carl Morrow; Matthias Egger; Olivia Keiser; Robin Wood
Journal:  Epidemics       Date:  2015-10-20       Impact factor: 4.396

6.  Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Authors:  Andrew Phillips; Amir Shroufi; Lara Vojnov; Jennifer Cohn; Teri Roberts; Tom Ellman; Kimberly Bonner; Christine Rousseau; Geoff Garnett; Valentina Cambiano; Fumiyo Nakagawa; Deborah Ford; Loveleen Bansi-Matharu; Alec Miners; Jens D Lundgren; Jeffrey W Eaton; Rosalind Parkes-Ratanshi; Zachary Katz; David Maman; Nathan Ford; Marco Vitoria; Meg Doherty; David Dowdy; Brooke Nichols; Maurine Murtagh; Meghan Wareham; Kara M Palamountain; Christine Chakanyuka Musanhu; Wendy Stevens; David Katzenstein; Andrea Ciaranello; Ruanne Barnabas; R Scott Braithwaite; Eran Bendavid; Kusum J Nathoo; David van de Vijver; David P Wilson; Charles Holmes; Anna Bershteyn; Simon Walker; Elliot Raizes; Ilesh Jani; Lisa J Nelson; Rosanna Peeling; Fern Terris-Prestholt; Joseph Murungu; Tsitsi Mutasa-Apollo; Timothy B Hallett; Paul Revill
Journal:  Nature       Date:  2015-12-03       Impact factor: 49.962

7.  Implementation of a point mutation assay for HIV drug resistance testing in Kenya.

Authors:  Horacio A Duarte; Ingrid A Beck; Molly Levine; Catherine Kiptinness; James M Kingoo; Bhavna Chohan; Samah R Sakr; Michael H Chung; Lisa M Frenkel
Journal:  AIDS       Date:  2018-10-23       Impact factor: 4.177

Review 8.  Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest?

Authors:  Ann M Dennis; Joshua T Herbeck; Andrew L Brown; Paul Kellam; Tulio de Oliveira; Deenan Pillay; Christophe Fraser; Myron S Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2014-10-01       Impact factor: 3.731

9.  Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

Authors:  Andrew N Phillips; Valentina Cambiano; Alec Miners; Paul Revill; Deenan Pillay; Jens D Lundgren; Diane Bennett; Elliott Raizes; Fumiyo Nakagawa; Andrea De Luca; Marco Vitoria; Jhoney Barcarolo; Joseph Perriens; Michael R Jordan; Silvia Bertagnolio
Journal:  Lancet HIV       Date:  2014-10-14       Impact factor: 12.767

10.  Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Authors:  Jeffrey W Eaton; Nicolas A Menzies; John Stover; Valentina Cambiano; Leonid Chindelevitch; Anne Cori; Jan A C Hontelez; Salal Humair; Cliff C Kerr; Daniel J Klein; Sharmistha Mishra; Kate M Mitchell; Brooke E Nichols; Peter Vickerman; Roel Bakker; Till Bärnighausen; Anna Bershteyn; David E Bloom; Marie-Claude Boily; Stewart T Chang; Ted Cohen; Peter J Dodd; Christophe Fraser; Chaitra Gopalappa; Jens Lundgren; Natasha K Martin; Evelinn Mikkelsen; Elisa Mountain; Quang D Pham; Michael Pickles; Andrew Phillips; Lucy Platt; Carel Pretorius; Holly J Prudden; Joshua A Salomon; David A M C van de Vijver; Sake J de Vlas; Bradley G Wagner; Richard G White; David P Wilson; Lei Zhang; John Blandford; Gesine Meyer-Rath; Michelle Remme; Paul Revill; Nalinee Sangrujee; Fern Terris-Prestholt; Meg Doherty; Nathan Shaffer; Philippa J Easterbrook; Gottfried Hirnschall; Timothy B Hallett
Journal:  Lancet Glob Health       Date:  2013-12-10       Impact factor: 26.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.